Marc Dunoyer, Alexion CEO (AstraZeneca via YouTube)

Up­dat­ed: As­traZeneca nabs a small rare dis­ease gene ther­a­py play­er for 667% pre­mi­um

As­traZeneca is kick­ing off the fourth quar­ter with a lit­tle M&A Mon­day for a gene edit­ing play­er re­cent­ly over­com­ing a sec­ond clin­i­cal hold to its on­ly pro­gram in hu­man stud­ies.

The Big Phar­ma and its sub­sidiary Alex­ion are buy­ing out lit­tle Log­icBio for $2.07 per share. That’s good for a mas­sive 667% pre­mi­um over its Fri­day clos­ing price, when it head­ed in­to the week­end at 27 cents and just weeks af­ter Nas­daq said Log­icBio would have to delist, which has been put on hold as the biotech re­quests a hear­ing. It’s one of two biotech deals to com­mence Oc­to­ber, along­side the news of In­cyte buy­ing a vi­tili­go-fo­cused biotech.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.